You are here

Eli Lilly

Eli Lilly-backed Symic raises $30M round as it preps for a pivotal trial

Eli Lilly-backed Symic raises $30M round as it preps for a pivotal trial

Endpoints

clinical trials

Flag link:

Nevada bill could force Sanofi, Novo and Lilly to reveal their insulin pricing secrets

Nevada bill could force Sanofi, Novo and Lilly to reveal their insulin pricing secrets

Fierce Pharma

Flag link:

Former Lilly employee wins an ironic lawsuit over disability benefits

Former Lilly employee wins an ironic lawsuit over disability benefits

Stat

Flag link:

7 Areas to watch from the ASCO abstracts

7 Areas to watch from the ASCO abstracts

BioPharma Dive

NewLink Genetics

Juno Therapeutics

Flag link:

ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say

ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say

Fierce Pharma

Flag link:

Playing catch-up, Eli Lilly is hustling positive PhIII CGRP migraine data to the FDA as late-stage rivalry heats up

Playing catch-up, Eli Lilly is hustling positive PhIII CGRP migraine data to the FDA as late-stage rivalry heats up

Endpoints

Flag link:

Novo’s diabetes medication Victoza keeps growing, despite Lilly’s market-share creep

Novo’s diabetes medication Victoza keeps growing, despite Lilly’s market-share creep

Fierce Pharma

Flag link:

These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016

These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016

Motley Fool

Flag link:

2 Reasons Eli Lilly is Getting Crushed

2 Reasons Eli Lilly is Getting Crushed

Barron's

Flag link:

Deal charge pushes drugmaker Eli Lilly to 1Q loss

Deal charge pushes drugmaker Eli Lilly to 1Q loss

Yahoo/AP

CoLucid Pharmaceuticals

Flag link:

[video]Eli Lilly CEO Says Diabetes Is ‘Core Engine’ to Strategy

[video]Eli Lilly CEO Says Diabetes Is ‘Core Engine’ to Strategy

Bloomberg

Flag link:

Eli Lilly’s 1Q17 Estimates for Elanco

Eli Lilly’s 1Q17 Estimates for Elanco

Market Realist

Flag link:

Eli Lilly says breast cancer combination treatment improved survival rates in late-stage trial

Eli Lilly says breast cancer combination treatment improved survival rates in late-stage trial

Marketwatch

advanced breast cancer

clinical trials

Flag link:

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from Novartis, Eli Lilly

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from Novartis, Eli Lilly

Endpoints

Valeant Pharmaceuticals

Flag link:

Meet the lawyer trying to pry drug pricing secrets out of Big Pharma

Meet the lawyer trying to pry drug pricing secrets out of Big Pharma

Stat

Flag link:

Growth Expected for Eli Lilly’s 1Q17 Revenue

Growth Expected for Eli Lilly’s 1Q17 Revenue

Market Realist

Flag link:

Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO

Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO

Endpoints

G1 Therapeutics

Flag link:

Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain

Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain

Motley Fool

rheumatoid arthritis

Flag link:

The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling

The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling

Yahoo/Business Insider

rheumatoid arthritis

Flag link:

Biotech Movers: OncoMed, Incyte, Omeros

Biotech Movers: OncoMed, Incyte, Omeros

TheStreet.com

small cell lung cancer

Flag link: